Treatment of Patients Over 64 Years of Age With Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—To evaluate the impact of renal impairment (RI) (estimated creatinine clearance [Clcr] <60 ml/min per 1.73 m2) and low baseline HbA1c (<7.5%) on comorbidity in patients with type 2 diabetes, and to assess the efficacy and safety of nateglinide monotherapy in these patients and in subgroups of patients over age 64 years (elderly) and elderly with RI. RESEARCH DESIGN AND METHODS—Retrospective subgroup analyses were performed on pooled data from all completed nateglinide studies (12 randomized, double blind trials and 1 open trial) in patients with type 2 diabetes. A total of 3,702 patients with ≥1 postbaseline safety evaluation received monotherapy with nateglinide (n = 2,204), metformin (n = 436), glyburide (n = 293), or placebo (n = 769). Efficacy (HbA1c) was evaluated in pooled data from four studies with similar design using 120 mg nateglinide (n = 544) versus placebo (n = 521). Evaluations were performed in the overall population and subgroups of patients over age 64 years. Specific considerations were given to RI, comorbidity, and baseline HbA1c. RESULTS—Patients over age 64 years (n = 1,170) represented 31.6% of the study population. Undiagnosed RI was common in the elderly with 83.4% of all patients being in this subgroup. Patients over 64 years with RI had a higher prevalence of cardio- and microvascular comorbidity compared with the overall population and all patients over age 64 years. Statistically significant HbA1c reductions versus placebo were observed with nateglinide in patients over age 64 years and elderly with RI patients at study end point (−0.9% and −1.1% in each subgroup, P < 0.01). Nateglinide was well tolerated with a low incidence of hypoglycemia in all subgroups, including those with RI and low baseline HbA1c. CONCLUSIONS—RI and comorbidity are common in patients over age 64 years with type 2 diabetes. Nateglinide was effective and well tolerated in all treated patients. In subgroups in which metformin and long-acting sulfonylureas must be used with caution, nateglinide had a low risk of adverse events and hypoglycemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Projection of Diabetes Burden Through 2050
Boyle, J. P., Honeycutt, A. A., Narayan, K. M. V., Hoerger, T. J., Geiss, L. S., Chen, H., & Thompson, T. J. (2001) · Diabetes Care · doi:10.2337/diacare.24.11.1936 · Cited by 1,004 · cited 1×
“CONCLUSIONS — Limited data on treatment of type 2 diabetes in older patients are available, although patients over age 64 years represent one-half of the diabetes population (1,2,5,27).”
Barrett-Connor, E., & Ferrara, A. (1998) · Diabetes Care · doi:10.2337/diacare.21.8.1236 · Cited by 369
Rates of hypoglycemia in users of sulfonylureas
Van Staa, T., Abenhaim, L., & Monette, J. (1997) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(97)00024-3 · Cited by 211 · cited 2×
“The increased risk of hypoglycemia in the elderly treated with SUs is well documented (11,12).”
Drug-Induced Hypoglycemic Coma in 102 Diabetic Patients
Ben-Ami, H., Nagachandran, P., Mendelson, A., & Edoute, Y. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.3.281 · Cited by 201
Hu, S., Wang, S., Fanelli, B., Bell, P. A., Dunning, B. E., Geisse, S., Schmitz, R., & Boettcher, B. R. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39254-7 · Cited by 78 · cited 1×
“Nateglinide is a novel oral glucose-lowering agent with a rapid onset of action and a short pharmacokinetic and pharmacodynamic half-life (13,14).”
Cited by
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Diabetic nephropathy: diagnosis, prevention, and treatment
Gross, J. L., de Azevedo, M. J., Silveiro, S. P., Canani, L. H., Caramori, M. L., & Zelmanovitz, T. (2005) · Diabetes Care · doi:10.2337/diacare.28.1.164 · Cited by 1,839
A review of the efficacy and safety of oral antidiabetic drugs
Stein, S. A., Lamos, E. M., & Davis, S. N. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.752813 · Cited by 305
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Spectrum · doi:10.2337/diaspect.25.3.154 · Cited by 286
Metadata
- Authors
- Del Prato, S., Heine, R. J., Keilson, L., Guitard, C., Shen, S. G., & Emmons, R. P.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2003-07-01
- Volume
- 26
- Issue
- 7
- Pages
- 2075-2080
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2160179123
- Cited by
- 64
- References
- 5
- FWCI
- 1.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of Patients Over 64 Years of Age With Type 2 Diabetes. https://app.cochat.ai/papers/10.2337/diacare.26.7.2075
- The paper
- Del Prato, S., Heine, R. J., Keilson, L., Guitard, C., Shen, S. G., & Emmons, R. P. (2003). Treatment of Patients Over 64 Years of Age With Type 2 Diabetes. Diabetes Care. https://doi.org/10.2337/diacare.26.7.2075
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.